Utama › Neuroblastoma › Massachusetts
Kajian klinikal Neuroblastoma di Massachusetts
13 kajian untuk Neuroblastoma sedang mencari peserta di lokasi di Massachusetts.
Bandar di Massachusetts
Teks kajian rasmi (Bahasa Inggeris)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 3
Sehingga umur 30 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Mengambil peserta
Semua umur · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06395103B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
Mengambil pesertaFasa 1
9 Months – 30 Years · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 3
365 Days – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
12 Months – 30 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 2 hingga 21 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 22 Jul 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
Mengambil pesertaFasa 2
Umur 1 hingga 31 · Semua jantina · Dikemas kini 20 Jul 2026 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1
Umur 1 hingga 30 · Semua jantina · Dikemas kini 14 Jul 2026 · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
Mengambil pesertaKajian pemerhatian
31 Days – 99 Years · Semua jantina · Dikemas kini 23 Mac 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
Mengambil peserta
Sehingga umur 17 · Semua jantina · Dikemas kini 10 Feb 2026 · NCT06831552Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Mengambil pesertaFasa 1/2
12 Months – 29 Years · Semua jantina · Dikemas kini 26 Dis 2025 · NCT06803875Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.